Keratoconus is a rare, progressive ophthalmic disorder characterized by changes to the cornea that result in significant ...

Credit: Glaukos. Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.

Epioxa from Glaukos is the first epithelium-on corneal cross-linking treatment that has been FDA approved in the United ...

SHERBORN, Mass.--(BUSINESS WIRE)--CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today published results of the EpiSmart cross-linking Phase ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In a previous blog post, I wrote about how soon after ...

A pediatric subgroup from a pivotal phase 3 trial randomized 2:1 showed epithelium-on oxygen-enriched CXL improved Kmax at 6 ...

(MASS APPEAL) – If you’ve been diagnosed with Keratoconus then Corneal Cross Linking might get you back to better eyesight. Mass Appeal’s Patrick Berry joined Dr. John P. Frangie, MD to learn more.

Glaukos Corporation GKOS recently announced the commercial availability of Epioxa, marking a significant milestone in its corneal health portfolio. The therapy stands out as the first FDA-approved, ...

Keratoconus is a progressive, noninflammatory corneal disorder that causes corneal thinning and irregularity, resulting in impaired vision. It typically begins in adolescence and progresses slowly ...

Understanding Keratoconus and Corneal Cross Linking Mass Appeal / May 16, 2025 / 02:14 PM EDT If you've been diagnosed with Keratoconus then Corneal Cross Linking might get you back to better eyesight ...